115 related articles for article (PubMed ID: 23581458)
21. The effect of hydroalcoholic Saffron (Crocus sativus L.) extract on fasting plasma glucose, HbA1c, lipid profile, liver, and renal function tests in patients with type 2 diabetes mellitus: A randomized double-blind clinical trial.
Moravej Aleali A; Amani R; Shahbazian H; Namjooyan F; Latifi SM; Cheraghian B
Phytother Res; 2019 Jun; 33(6):1648-1657. PubMed ID: 30942510
[TBL] [Abstract][Full Text] [Related]
22. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
Aronoff S; Rosenblatt S; Braithwaite S; Egan JW; Mathisen AL; Schneider RL
Diabetes Care; 2000 Nov; 23(11):1605-11. PubMed ID: 11092281
[TBL] [Abstract][Full Text] [Related]
23. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
Kipnes MS; Krosnick A; Rendell MS; Egan JW; Mathisen AL; Schneider RL
Am J Med; 2001 Jul; 111(1):10-7. PubMed ID: 11448655
[TBL] [Abstract][Full Text] [Related]
24. Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis.
Allen RW; Schwartzman E; Baker WL; Coleman CI; Phung OJ
Ann Fam Med; 2013; 11(5):452-9. PubMed ID: 24019277
[TBL] [Abstract][Full Text] [Related]
25. Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study.
Dailey GE; Mohideen P; Fiedorek FT
Clin Ther; 2002 Sep; 24(9):1426-38. PubMed ID: 12380634
[TBL] [Abstract][Full Text] [Related]
26. Chinese herbal medicine for impaired glucose tolerance: a randomized placebo controlled trial.
Grant SJ; Chang DH; Liu J; Wong V; Kiat H; Bensoussan A
BMC Complement Altern Med; 2013 May; 13():104. PubMed ID: 23672597
[TBL] [Abstract][Full Text] [Related]
27. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.
Hollander PA; Elbein SC; Hirsch IB; Kelley D; McGill J; Taylor T; Weiss SR; Crockett SE; Kaplan RA; Comstock J; Lucas CP; Lodewick PA; Canovatchel W; Chung J; Hauptman J
Diabetes Care; 1998 Aug; 21(8):1288-94. PubMed ID: 9702435
[TBL] [Abstract][Full Text] [Related]
28.
Rao AS; Hegde S; Pacioretty LM; DeBenedetto J; Babish JG
J Med Food; 2020 Sep; 23(9):905-919. PubMed ID: 32758056
[TBL] [Abstract][Full Text] [Related]
29. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.
Fonseca VA; Rosenstock J; Wang AC; Truitt KE; Jones MR
Diabetes Care; 2008 Aug; 31(8):1479-84. PubMed ID: 18458145
[TBL] [Abstract][Full Text] [Related]
30. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
Rajagopalan R; Xu Y; Abbadessa M;
Am J Geriatr Pharmacother; 2006 Jun; 4(2):123-33. PubMed ID: 16860259
[TBL] [Abstract][Full Text] [Related]
31. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
[TBL] [Abstract][Full Text] [Related]
32. Effects of Juglans regia L. leaf extract on hyperglycemia and lipid profiles in type two diabetic patients: a randomized double-blind, placebo-controlled clinical trial.
Hosseini S; Jamshidi L; Mehrzadi S; Mohammad K; Najmizadeh AR; Alimoradi H; Huseini HF
J Ethnopharmacol; 2014 Mar; 152(3):451-6. PubMed ID: 24462785
[TBL] [Abstract][Full Text] [Related]
33. Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR study.
Brinton EA; Ballantyne CM; Bays HE; Kastelein JJ; Braeckman RA; Soni PN
Cardiovasc Diabetol; 2013 Jul; 12():100. PubMed ID: 23835245
[TBL] [Abstract][Full Text] [Related]
34. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study.
Coniff RF; Shapiro JA; Robbins D; Kleinfield R; Seaton TB; Beisswenger P; McGill JB
Diabetes Care; 1995 Jun; 18(6):817-24. PubMed ID: 7555508
[TBL] [Abstract][Full Text] [Related]
35. A Randomized Controlled Trial of a Herbal Compound for Improving Metabolic Parameters in Diabetic Patients with Uncontrolled Dyslipidemia.
Ghorbani A; Zarvandi M; Rakhshandeh H
Endocr Metab Immune Disord Drug Targets; 2019; 19(7):1075-1082. PubMed ID: 30727929
[TBL] [Abstract][Full Text] [Related]
36. Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
Buse JB; Rubin CJ; Frederich R; Viraswami-Appanna K; Lin KC; Montoro R; Shockey G; Davidson JA
Clin Ther; 2005 Aug; 27(8):1181-95. PubMed ID: 16199244
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
[TBL] [Abstract][Full Text] [Related]
38. Effect of vildagliptin on glucose and insulin concentrations during a 24-hour period in type 2 diabetes patients with different ranges of baseline hemoglobin A1c levels.
González-Ortiz M; Sánchez-Peña MJ; González-Ortiz LJ; Robles-Cervantes JA; García-Ortega YE; Gómez-Gaitán EA; Pérez-Rubio KG; Martínez-Abundis E
Diabetes Technol Ther; 2013 Jul; 15(7):564-8. PubMed ID: 23617250
[TBL] [Abstract][Full Text] [Related]
39. Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent.
Lirussi F; Beccarello A; Zanette G; De Monte A; Donadon V; Velussi M; Crepaldi G
Diabetes Nutr Metab; 2002 Aug; 15(4):222-31. PubMed ID: 12416659
[TBL] [Abstract][Full Text] [Related]
40. Improved glycemic control and lipid profile in hyperlipidemic type 2 diabetic patients consuming Salvia officinalis L. leaf extract: a randomized placebo. Controlled clinical trial.
Kianbakht S; Dabaghian FH
Complement Ther Med; 2013 Oct; 21(5):441-6. PubMed ID: 24050577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
